Amiselimod hydrochloride is under clinical development by Mitsubishi Tanabe Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Amiselimod hydrochloride’s likelihood of approval (LoA) and phase transition for Ulcerative Colitis took place on 21 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Amiselimod hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Amiselimod hydrochloride overview

Amiselimod hydrochloride (MT-1303) is under development for the treatment of relapsing-remitting multiple sclerosis, ulcerative colitis and Crohn's disease. The drug candidate administered orally as a capsule. MT-1303 is a sphingosine 1-phosphate (S1P) receptor-1 antagonist. It was also under development for the treatment of ulcerative colitis moderate to severe chronic plaque psoriasis and systemic lupus erythematosus.

Mitsubishi Tanabe Pharma overview

Mitsubishi Tanabe Pharma (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over the counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.

Quick View Amiselimod hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Amiselimod hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Immunology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.